Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


Articles published in Leukemia

Retrieve available abstracts of 71 articles:
HTML format
Text format



Single Articles


    April 2018
  1. HU T, Wu Q, Chong Y, Qin H, et al
    FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0124.
    PubMed     Text format     Abstract available


    March 2018
  2. SCHLEUSSNER N, Merkel O, Costanza M, Liang HC, et al
    The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
    Leukemia. 2018 Mar 28. pii: 10.1038/s41375-018-0045.
    PubMed     Text format     Abstract available


  3. SUN W, Malvar J, Sposto R, Verma A, et al
    Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
    Leukemia. 2018 Mar 15. pii: 10.1038/s41375-018-0094.
    PubMed     Text format     Abstract available


    February 2018
  4. GALLARDO F, Bertran J, Lopez-Arribillaga E, Gonzalez J, et al
    Novel phosphorylated TAK1 species with functional impact on NF-kappaB and beta-catenin signaling in human Cutaneous T-cell lymphoma.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0066.
    PubMed     Text format     Abstract available


  5. ARAF S, Wang J, Korfi K, Pangault C, et al
    Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.
    Leukemia. 2018 Feb 8. pii: 10.1038/s41375-018-0043.
    PubMed     Text format    


  6. NAIRISMAGI M-, Gerritsen ME, Li ZM, Wijaya GC, et al
    Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0004.
    PubMed     Text format     Abstract available


  7. RULE S, Jurczak W, Jerkeman M, Rusconi C, et al
    Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0023.
    PubMed     Text format    


    November 2017
  8. HARTMANN K, Illing A, Leithauser F, Baisantry A, et al
    Gene dosage reductions of Trf1 and/or Tin2 induce telomere DNA damage and lymphoma formation in aging mice.
    Leukemia. 2017 Nov 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  9. GERMINI D, Tsfasman T, Klibi M, El-Amine R, et al
    HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells.
    Leukemia. 2017;31:2515-2522.
    PubMed     Text format     Abstract available


    October 2017
  10. HU G, Dasari S, Asmann YW, Greipp PT, et al
    Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.
    Leukemia. 2017 Oct 13. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  11. SOMMERMEYER D, Hill T, Shamah SM, Salter AI, et al
    Fully human CD19-specific chimeric antigen receptors for T-cell therapy.
    Leukemia. 2017;31:2191-2199.
    PubMed     Text format     Abstract available


  12. CHEN KH, Wada M, Pinz KG, Liu H, et al
    Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Leukemia. 2017;31:2151-2160.
    PubMed     Text format     Abstract available


    September 2017
  13. JIA YJ, Liu ZB, Wang WG, Sun CB, et al
    HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
    Leukemia. 2017 Sep 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  14. VRZALIKOVA K, Ibrahim M, Vockerodt M, Perry T, et al
    S1PR1 drives a feed forward signalling loop to regulate BATF3 and the transcriptional programme of hodgkin lymphoma cells.
    Leukemia. 2017 Sep 7. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    August 2017
  15. FUJISAWA M, Sakata-Yanagimoto M, Nishizawa S, Komori D, et al
    Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.
    Leukemia. 2017 Aug 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  16. ZAMO A, Pischimarov J, Schlesner M, Rosenstiel P, et al
    Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole exome sequencing.
    Leukemia. 2017 Aug 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  17. KARUBE K, Enjuanes A, Dlouhy I, Jares P, et al
    Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    July 2017
  18. CHEADLE EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, et al
    A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  19. YAO Z, Deng L, Xu-Monette ZY, Manyam GC, et al
    Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
    Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  20. JAIN N, Zhu H, Khashab T, Ye Q, et al
    Targeting nucleolin for better survival in diffuse large B-cell lymphoma.
    Leukemia. 2017 Jul 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    June 2017
  21. SUN B, Fiskus W, Qian Y, Rajapakshe K, et al
    BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
    Leukemia. 2017 Jun 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  22. LOLLIES A, Hartmann S, Schneider M, Bracht T, et al
    An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
    Leukemia. 2017 Jun 29. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    May 2017
  23. KASENDA B, Ihorst G, Schroers R, Korfel A, et al
    High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma-a prospective multicentre trial by the German cooperative PCNSL study group.
    Leukemia. 2017 May 31. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    April 2017
  24. VAN DER MEULEN M, Dinmohamed AG, Visser O, Doorduijn JK, et al
    Improved survival in primary central nervous system lymphoma up to age 70 only: A population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015.
    Leukemia. 2017 Apr 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    March 2017
  25. ATSAVES V, Tsesmetzis N, Chioureas D, Kis L, et al
    PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large cell lymphoma.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  26. DZIKIEWICZ-KRAWCZYK A, Kok K, Slezak-Prochazka I, Robertus JL, et al
    ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma.
    Leukemia. 2017 Mar 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    February 2017
  27. WOLFSON J, Sun CL, Wyatt L, Stock W, et al
    Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin Lymphoma.
    Leukemia. 2017 Feb 20. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    January 2017
  28. SELVARAJAN V, Osato M, Nah GS, Yan J, et al
    RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC.
    Leukemia. 2017 Jan 25. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  29. MONJEZI R, Miskey C, Gogishvili T, Schleef M, et al
    Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
    Leukemia. 2017;31:186-194.
    PubMed     Text format     Abstract available


  30. RUELLA M, Kenderian SS, Shestova O, Klichinsky M, et al
    Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.
    Leukemia. 2017;31:246-248.
    PubMed     Text format    


    December 2016
  31. ROSSILLE D, Azzaoui I, Feldman AL, Maurer MJ, et al
    Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: A replication study and combined analysis of 508 patients.
    Leukemia. 2016 Dec 30. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    November 2016
  32. CHEADLE EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, et al
    A TLR7 agonist enhances the anti-tumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
    Leukemia. 2016 Nov 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  33. DING H, Peterson KL, Correia C, Koh B, et al
    Histone deacetylase inhibitors interrupt HSP90 RASGRP1 and HSP90 CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
    Leukemia. 2016 Nov 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  34. FRITSCH K, Kasenda B, Schorb E, Hau P, et al
    High-dose methotrexate based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN-study).
    Leukemia. 2016 Nov 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  35. BAER C, Dicker F, Kern W, Haferlach T, et al
    Genetic characterization of MYD88 mutated lymphoplasmacytic lymphoma in comparison to MYD88 mutated chronic lymphocytic leukemia.
    Leukemia. 2016 Nov 14. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  36. PALACIOS G, Shaw T, Li Y, Singh RK, et al
    Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex.
    Leukemia. 2016 Nov 14. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    October 2016
  37. PIAO W, Chau D, Yue LM, Kwong YL, et al
    Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  38. SMITH MR, Hong F, Li H, Gordon LI, et al
    Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499.
    Leukemia. 2016 Oct 26. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  39. POMARI E, Basso G, Bresolin S, Pillon M, et al
    NPM-ALK expression levels identify two distinct subtypes of pediatric anaplastic large cell lymphoma.
    Leukemia. 2016 Oct 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    September 2016
  40. REDDY NM, Greer JP, Morgan DS, Chen H, et al
    A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
    Leukemia. 2016 Sep 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    August 2016
  41. XIA Y, Xu-Monette ZY, Tzankov A, Li X, et al
    Loss of PRDM1/BLIMP-1 function contributes to poor prognosis for activated B-cell-like diffuse large B-cell lymphoma.
    Leukemia. 2016 Aug 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  42. BONSIGNORE L, Passelli K, Pelzer C, Perroud M, et al
    A role for MALT1 activity in Kaposi's sarcoma-associated herpesvirus latency and growth of primary effusion lymphoma.
    Leukemia. 2016 Aug 19. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  43. WURSTER KD, Hummel F, Richter J, Giefing M, et al
    Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.
    Leukemia. 2016 Aug 19. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  44. SLABICKI M, Lee KS, Jethwa A, Sellner L, et al
    Dissection of CD20 regulation in lymphoma using RNAi.
    Leukemia. 2016 Aug 18. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  45. LINKE F, Harenberg M, Nietert MM, Zaunig S, et al
    Microenvironmental interactions between endothelial and lymphoma cells-a role for the canonical WNT pathway in Hodgkin lymphoma.
    Leukemia. 2016 Aug 18. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  46. LOCATELLI SL, Careddu G, Inghirami G, Castagna L, et al
    The novel PI3K-delta inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.
    Leukemia. 2016 Aug 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    July 2016
  47. PIZZI M, Boi M, Bertoni F, Inghirami G, et al
    Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.
    Leukemia. 2016 Jul 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  48. BOUSKA A, Zhang W, Gong Q, Iqbal J, et al
    Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.
    Leukemia. 2016 Jul 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    June 2016
  49. VASSILAKOPOULOS TP, Papageorgiou S, Pangalis GA, Chatziioannou S, et al
    Response to 'PET after response to R-CHOP in primary mediastinal large B-cell lymphoma'.
    Leukemia. 2016 Jun 3. doi: 10.1038/leu.2016.
    PubMed     Text format    


    May 2016
  50. JUSKEVICIUS D, Lorberl T, Gsponer J, Perrina V, et al
    Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome wide copy number aberration and targeted sequencing analysis.
    Leukemia. 2016 May 20. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  51. LONTOS K
    PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP.
    Leukemia. 2016 May 17. doi: 10.1038/leu.2016.
    PubMed     Text format    


  52. DIETRICH S, Finel H, Martinez C, Tischer J, et al
    Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: A registry study by the European society for blood and marrow transplantation.
    Leukemia. 2016 May 5. doi: 10.1038/leu.2016.
    PubMed     Text format    


    April 2016
  53. LEICH E, Hoster E, Wartenberg M, Unterhalt M, et al
    Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus.
    Leukemia. 2016;30:854-60.
    PubMed     Text format     Abstract available


  54. WAANDERS E, Hebeda KM, Kamping EJ, Groenen PJ, et al
    Independent development of lymphoid and histiocytic malignancies from a shared early precursor.
    Leukemia. 2016;30:955-8.
    PubMed     Text format    


    March 2016
  55. SHIMADA K, Shimada S, Sugimoto K, Nakatochi M, et al
    Development and analysis of patient derived xenograft mouse models in intravascular large B-cell lymphoma.
    Leukemia. 2016 Mar 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  56. GONDEK LP, Zheng G, Ghiaur G, DeZern AE, et al
    Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.
    Leukemia. 2016 Mar 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  57. SPINNER S, Crispatzu G, Yi JH, Munkhbaatar E, et al
    Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  58. MA J, Nie K, Redmond D, Liu Y, et al
    EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis.
    Leukemia. 2016;30:594-604.
    PubMed     Text format     Abstract available


  59. PINZ K, Liu H, Golightly M, Jares A, et al
    Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells.
    Leukemia. 2016;30:701-7.
    PubMed     Text format     Abstract available


  60. BROWN PJ, Wong KK, Felce SL, Lyne L, et al
    FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Leukemia. 2016;30:605-16.
    PubMed     Text format     Abstract available


  61. FRANK C, Fallah M, Chen T, Mai EK, et al
    Search for familial clustering of multiple myeloma with any cancer.
    Leukemia. 2016;30:627-32.
    PubMed     Text format     Abstract available


  62. TEO AE, Chen Z, Miranda RN, McDonnell T, et al
    Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.
    Leukemia. 2016;30:580-93.
    PubMed     Text format     Abstract available


    February 2016
  63. MIRANDA MB, Lauseker M, Kraus MP, Proetel U, et al
    Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment- long-term observation in CML Study IV.
    Leukemia. 2016 Feb 9. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  64. NAIRISMAGI ML, Tan J, Lim JQ, Nagarajan S, et al
    JAK-STAT and G protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma.
    Leukemia. 2016 Feb 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    January 2016
  65. DIVAKAR SK, Ramana Reddy MV, Cosenza SC, Baker SJ, et al
    Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.
    Leukemia. 2016;30:86-93.
    PubMed     Text format     Abstract available


    December 2015
  66. PALOMERO J, Vegliante MC, Eguileor A, Rodriguez ML, et al
    SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6.
    Leukemia. 2015 Dec 29. doi: 10.1038/leu.2015.
    PubMed     Text format    


  67. HARTMANN S, Schuhmacher B, Rausch T, Fuller L, et al
    Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.
    Leukemia. 2015 Dec 10. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


    November 2015
  68. HOSTER E, Geisler CH, Doorduijn J, van der Holt B, et al
    Total body irradiation after high-dose cytarabine in mantle cell lymphoma: A comparison of Nordic MCL2, HOVON-45, and European MCLYounger trials.
    Leukemia. 2015 Nov 24. doi: 10.1038/leu.2015.
    PubMed     Text format    


  69. EICHENAUER DA, Goergen H, Plutschow A, Wongso D, et al
    Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: Results of a phase II study from the German Hodgkin study group.
    Leukemia. 2015 Nov 20. doi: 10.1038/leu.2015.
    PubMed     Text format    


    October 2015
  70. FUJII K, Karpova MB, Asagoe K, Georgiev O, et al
    Versican upregulation in Sezary cells alters growth, motility and resistance to chemotherapy.
    Leukemia. 2015;29:2024-32.
    PubMed     Text format     Abstract available


    September 2015
  71. JEONG D, Kim J, Nam J, Sun H, et al
    MicroRNA-124 links p53 to the NF-kappaB pathway in B-cell lymphomas.
    Leukemia. 2015;29:1868-74.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: